AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31152533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex massages and physical training procedures
Number of subjects: 50
Study 31152533 — intervention group
Group type: COMPARATOR
Intervention: Individually selected training
Number of subjects: 50
Study 26467810 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing wedge high tibial osteotomy (CW HTO)
Number of subjects: 70
Study 26467810 — intervention group
Group type: COMPARATOR
Intervention: Opening wedge high tibial osteotomy (OW HTO)
Number of subjects: 70
Study 26467810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (CW and OW HTO)
Number of subjects: 70
Study 26340658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised tobramycin (300 mg twice daily for 3 months)
Number of subjects: 35
Study 26340658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26340658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised tobramycin
Number of subjects: 35
Study 23879671 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1500 mg/week for four weeks)
Number of subjects: 10
Study 21278137 — intervention group
Group type: COMPARATOR
Intervention: Younger control (Y-C)
Number of subjects: 101
Study 21278137 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure functional class III (HF-III)
Number of subjects: 101
Study 21278137 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure functional class II (HF-II)
Number of subjects: 101
Study 21278137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output or Δ[THb](FC)
Number of subjects: 101
Study 19180378 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of randomization in clinical trials
Number of subjects: 0
Study 19180378 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 0
Study 16721298 — intervention group
Group type: EXPERIMENTAL
Intervention: PLF
Number of subjects: 167
Study 16721298 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF
Number of subjects: 167
Study 16721298 — intervention group
Group type: EXPERIMENTAL
Intervention: PLF+PLIF
Number of subjects: 167
Study 15541405 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of levonorgestrel (LNG)
Number of subjects: 58
Study 15541405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 0.75-mg dose of levonorgestrel (half dose)
Number of subjects: 58
Study 15541405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11704378 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 47
Study 11704378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9048281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (group 1, n = 24)
Number of subjects: 50
Study 9048281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (group 2, n = 26)
Number of subjects: 50
Study 7526868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) substance P (SP) levels in FMS patients
Number of subjects: 32
Study 7526868 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 32
Study 2564505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline ethylenediamine (aminophylline), 7 mg/kg
Number of subjects: 20
Study 2564505 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of theophylline (375 mg)
Number of subjects: 20
Study 2564505 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of theophylline ethylenediamine
Number of subjects: 20
Study 170949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynarin (3,5‐dihydroxy‐1,4‐bis‐(3,4‐dihydroxy‐cinnamoyloxy)‐cyclohexan‐carbonic acid) for 50 days
Number of subjects: 60
Study 170949 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 50 days
Number of subjects: 60
Study 30716942 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic group (SG): 40 g of extruded sorghum plus 100 mL of unfermented probiotic milk
Number of subjects: 58
Study 30716942 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): 40 g of extruded corn plus 100 mL of pasteurized milk
Number of subjects: 58
Study 28747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic Load (GL)
Number of subjects: 269
Study 28747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI)
Number of subjects: 269
Study 28747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids (PUFAs)
Number of subjects: 269
Study 28747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble Fiber
Number of subjects: 269
Study 25934170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 174
Study 25934170 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT
Number of subjects: 174
Study 25934170 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 174
Study 23882452 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splint in situ
Number of subjects: 10
Study 23882452 — intervention group
Group type: COMPARATOR
Intervention: Nights without the stabilization splint in situ
Number of subjects: 10
Study 21365345 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST), n=10
Number of subjects: 25
Study 21365345 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT), n=10
Number of subjects: 25
Study 21365345 — intervention group
Group type: COMPARATOR
Intervention: Control (C), n=5
Number of subjects: 25
Study 19324952 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD cases (male)
Number of subjects: 894
Study 19324952 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD cases (female)
Number of subjects: 894
Study 19324952 — intervention group
Group type: COMPARATOR
Intervention: Controls (male)
Number of subjects: 894
Study 19324952 — intervention group
Group type: COMPARATOR
Intervention: Controls (female)
Number of subjects: 894
Study 17419259 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (continuous infusion for 48 hours)
Number of subjects: 68
Study 17419259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (continuous infusion for 48 hours)
Number of subjects: 68
Study 15266769 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of meloxicam (Group M, n = 27)
Number of subjects: 52
Study 15266769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P, n = 25)
Number of subjects: 52
Study 11504270 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral [14C]omapatrilat
Number of subjects: 12
Study 11504270 — intervention group
Group type: COMPARATOR
Intervention: 20 mg intravenous [14C]omapatrilat
Number of subjects: 12
Study 9655309 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained DVT
Number of subjects: 326
Study 9655309 — intervention group
Group type: COMPARATOR
Intervention: Secondary DVT
Number of subjects: 326
Study 7826786 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 6 mg kg‐1 at 21:00 and placebo at 06:30
Number of subjects: 104
Study 7826786 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo at 21:00 and nizatidine 6 mg kg‐1 at 06:30
Number of subjects: 104
Study 7826786 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 3 mg kg‐1 at 21:00 and 06:30
Number of subjects: 104
Study 7826786 — intervention group
Group type: COMPARATOR
Intervention: placebo‐placebo (control)
Number of subjects: 104
Study 7826786 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo‐nizatidine
Number of subjects: 104
Study 7826786 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine‐nizatidine
Number of subjects: 104
Study 3258578 — intervention group
Group type: EXPERIMENTAL
Intervention: Large varices at endoscopy
Number of subjects: 58
Study 3258578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic vein pressure gradient
Number of subjects: 58
Study 3258578 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance
Number of subjects: 58
Study 3258578 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous variceal bleeding
Number of subjects: 58
Study 3258578 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Child‐Turcotte's criteria and incapacitation index
Number of subjects: 58
Study 30236867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 40
Study 30236867 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 40
Study 30236867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27481017 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone administration
Number of subjects: 127
Study 24725355 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms plus emergency contraception pills (ECP) (Levonorgestrel)
Number of subjects: 1562
Study 24725355 — intervention group
Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1562
Study 23830355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily
Number of subjects: 715
Study 23830355 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 715
Study 20628385 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 84
Study 20628385 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (G)
Number of subjects: 84
Study 18250132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic capacity (maximal oxygen uptake/VO2 max) measured with a bicycle ergometer exercise test
Number of subjects: 34
Study 18250132 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (L/min, mL/min/kg)
Number of subjects: 34
Study 18250132 — intervention group
Group type: COMPARATOR
Intervention: Overall disease activity assessed with Systemic Lupus Activity Measure (SLAM) and modified SLE-DAI
Number of subjects: 34
Study 18250132 — intervention group
Group type: COMPARATOR
Intervention: Overall organ damage assessed with SLICC/(ACR)-DI
Number of subjects: 34
Study 18250132 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (HRQL) assessed with the 36-item Short-form health-survey (SF-36)
Number of subjects: 34
Study 18250132 — intervention group
Group type: COMPARATOR
Intervention: Physical activity assessed with a self-assessed question
Number of subjects: 34
Study 16377065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 1000 IU hCG
Number of subjects: 36
Study 16377065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 500 IU hCG
Number of subjects: 36
Study 16377065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 250 mg progesterone
Number of subjects: 36
Study 12686241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost combination (hydroxypropyl methylcellulose 2% (Ocucoat) and Ringer's solution)
Number of subjects: 45
Study 12686241 — intervention group
Group type: COMPARATOR
Intervention: Expensive combination (sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) and BSS Plus)
Number of subjects: 45
Study 12686241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low-cost and expensive combinations)
Number of subjects: 45
Study 12686241 — intervention group
Group type: COMPARATOR
Intervention: Expensive combination (Viscoat and BSS Plus)
Number of subjects: 45
Study 11095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculodissection (LTD) using a 193 nm photopolishing, scanning excimer laser system
Number of subjects: 8
Study 11095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculodissection (LTD)
Number of subjects: 8
Study 9370845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.20 mg.kg‐1
Number of subjects: 60
Study 9370845 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium 0.15 mg.kg‐1
Number of subjects: 60
Study 7519694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release verapamil and ACE inhibition by trandolapril
Number of subjects: 0
Study 2885187 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.2 mg/kg
Number of subjects: 50
Study 2885187 — intervention group
Group type: COMPARATOR
Intervention: morphine 0.2 mg/kg
Number of subjects: 50
Study 31062377 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk (0.2 mL of mother's colostrum or milk prior to gavage feeding)
Number of subjects: 200
Study 31062377 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk
Number of subjects: 200
Study 30238798 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey ready-to-use supplementary food (RUSF)
Number of subjects: 2259
Study 30238798 — intervention group
Group type: COMPARATOR
Intervention: Soy ready-to-use supplementary food (RUSF)
Number of subjects: 2259
Study 27068872 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction (index <1.67)
Number of subjects: 70
Study 27068872 — intervention group
Group type: COMPARATOR
Intervention: Normal endothelial function (index ≥1.67)
Number of subjects: 70
Study 27068872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus at baseline
Number of subjects: 70
Study 27068872 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of diabetes mellitus
Number of subjects: 70
Study 25639278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST)
Number of subjects: 462
Study 25639278 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT)
Number of subjects: 462
Study 25639278 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT)
Number of subjects: 462
Study 23107871 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 150 mg of vismodegib for 7 days
Number of subjects: 0
Study 23107871 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 400 mg of moxifloxacin
Number of subjects: 0
Study 23107871 — intervention group
Group type: COMPARATOR
Intervention: Placebo for vismodegib
Number of subjects: 0
Study 23107871 — intervention group
Group type: COMPARATOR
Intervention: Placebo for moxifloxacin
Number of subjects: 0
Study 21347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported exercise programme (3 60-min supported + 2 unsupported sessions per week)
Number of subjects: 19
Study 21347968 — intervention group
Group type: COMPARATOR
Intervention: Standard care programme (advice to exercise at moderate to high intensity for 30 min five times a week)
Number of subjects: 19
Study 18303468 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery versus conservative treatments (17 NRSs and 8 RCTs)
Number of subjects: 43
Study 18303468 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with fusion versus surgery without fusion (17 NRSs and 3 RCTs)
Number of subjects: 43
Study 18303468 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented fusion versus noninstrumented fusion (15 NRSs and 8 RCTs)
Number of subjects: 43
Study 16724235 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 124
Study 16724235 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEpo)
Number of subjects: 124
Study 12559135 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Symptom Checklist
Number of subjects: 2052
Study 12559135 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Locus of Control Scale
Number of subjects: 2052
Study 12559135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy Scale
Number of subjects: 2052
Study 12559135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐esteem Scale
Number of subjects: 2052
Study 10895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard padded with a gurney mattress and eggcrate foam
Number of subjects: 0
Study 10895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard padded with a gurney mattress
Number of subjects: 0
Study 10895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard padded with a folded blanket
Number of subjects: 0
Study 10895921 — intervention group
Group type: COMPARATOR
Intervention: Backboard alone
Number of subjects: 0
Study 8923359 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT 100 IU/day and calcium (Ca) 500 mg/day
Number of subjects: 32
Study 8923359 — intervention group
Group type: COMPARATOR
Intervention: Calcium (Ca) alone
Number of subjects: 32
Study 1557921 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 120
Study 1557921 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 120
Study 3535473 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem therapy for 14 days
Number of subjects: 0
Study 3535473 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31591010 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic Alignment (KA) TKA
Number of subjects: 41
Study 31591010 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Alignment (MA) TKA
Number of subjects: 41
Study 31591010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both KA and MA TKA
Number of subjects: 41
Study 30352059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention targeting physical activity, diet, and behavior modification for six months.
Number of subjects: 577
Study 30352059 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving prompt infertility care as usual.
Number of subjects: 577
Study 27207552 — intervention group
Group type: EXPERIMENTAL
Intervention: tRES-HESP coformulation
Number of subjects: 29
Study 25034409 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP training program (one day face-to-face training with online support)
Number of subjects: 54
Study 25034409 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study 23180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0
Study 23180065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22432517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre (GS) supplementation at 500 mg per day for 3 months
Number of subjects: 0
Study 22432517 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15960558 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants (primarily fluoxetine, duration 6 to 12 weeks)
Number of subjects: 171
Study 15960558 — intervention group
Group type: COMPARATOR
Intervention: First-generation antidepressants (including placebo, phenelzine, and imipramine, N = 420)
Number of subjects: 171
Study 12638101 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and gait analysis
Number of subjects: 20
Study 10338172 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg morphine + 30 mg ketorolac (group KM)
Number of subjects: 100
Study 10338172 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac (group K60)
Number of subjects: 100
Study 10338172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 100
Study 10338172 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg morphine (group M)
Number of subjects: 100
Study 10338172 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac (group K30)
Number of subjects: 100
Study 7796236 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40
Study 7796236 — intervention group
Group type: COMPARATOR
Intervention: Synchronous Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 40
Study 1938398 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated activated charcoal xerodressing (SIAX)
Number of subjects: 40
Study 1938398 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (phase-adapted therapy using diverse topical modalities)
Number of subjects: 40
Study 7229121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenously)
Number of subjects: 6
Study 7229121 — intervention group
Group type: COMPARATOR
Intervention: Histamine (10 microgram/min for 20 minutes)
Number of subjects: 6
Study 31299352 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO-based management
Number of subjects: 220
Study 31299352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 31299352 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO group
Number of subjects: 220
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (25 mg)
Number of subjects: 0
Study 30222962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid treatment
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NAS > 5
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline triglyceride level ≤ 154 mg/dL
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline international normalized ratio ≤ 1
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline aspartate aminotransferase level ≤ 49 U/L
Number of subjects: 0
Study 30222962 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in alanine aminotransferase level at week 24 by 17 U/L or more
Number of subjects: 0
Study 27398920 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Drop Jump (HDJ)
Number of subjects: 18
Study 27398920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Drop Jump (VDJ)
Number of subjects: 18
Study 26378687 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8505
Study 22760341 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day combined clavulanate/amoxicillin preparation
Number of subjects: 97
Study 22760341 — intervention group
Group type: COMPARATOR
Intervention: 10-day amoxicillin treatment
Number of subjects: 97
Study 21951412 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART program (standard medical management for secondary prevention of ischemic stroke)
Number of subjects: 4074
Study 19678461 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 167
Study 19678461 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided meditation
Number of subjects: 167
Study 19678461 — intervention group
Group type: COMPARATOR
Intervention: Active control (visits from hospice-trained volunteers)
Number of subjects: 167